Skip to main content

Table 2 Emerging treatments with potential for targeting atherogenic dyslipidaemia

From: Residual macrovascular risk in 2013: what have we learned?

   Effects on atherogenic dyslipidaemia* Other effects Outstanding issues
Treatment group/example Dose Triglycerides HDL-C   
[reference]; duration
SPPARMs: K-877 [81] 100 μg BID ↓70% ↑18% Improved safety profile (CV, renal and hepatic biomarkers) versus fenofibrate Outcomes data, long-term safety
12 weeks
Dual PPAR agonists      
GFT505 (dual PPARα/δ) [84] 80 mg OD ↓17-25% ↑8-9% Improved safety profile (hepatic biomarkers) Lower efficacy than current PPARα agonists
4 weeks Outcomes data, long-term safety
CETP inhibitors
Anacetrapib1[85] 100 mg OD ↓7% ↑138% Decreases in LDL-C (~40%), Lp(a) and apoB Outcomes data, long-term safety
24 weeks
Evacetrapib1[86] 100 mg OD NA ↑~80% Decreases in LDL-C (36%); data on other lipid effects NA Outcomes data, long-term safety
12 weeks
PCSK9 targeted therapy      
Alirocumab1[87] 150 mg every 2 weeks ↓19% ↑6% Decreases in LDL-C (>60%); also Lp(a) and apoB Outcomes data, long-term safety
12 weeks
AMG 1451,2[88] 140 mg every 2 weeks ↓34% ↑8% Decreases in LDL-C (>60%), Lp(a) and apoB Outcomes data, long-term safety
12 weeks
  1. *Placebo-adjusted effect; 1Change from baseline in combination with a statin; 2AMG 145 is now referred to as evolocumab BID twice daily; apo apolipoprotein; CETP cholesteryl ester transfer protein; CV cardiovascular; LDL-C low-density lipoprotein cholesterol; Lp(a) lipoprotein(a); NA not available; OD once daily; PCSK9 proprotein convertase subtilisin/kexin type 9; PPAR peroxisome proliferator-activated receptor; SPPARMs Selective peroxisome proliferator-activated receptor modulators.